GlassScriptPhysician profile
Arvinder S Bir
NPI 1417164898
$74,345.36
in general payments reported to CMS, 2019-2025
87 companies · $2,240 in 2025
The $2,240 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $11K · 2021: $7,089 · 2022: $2,476 · 2023: $2,824 · 2024: $2,660 · 2025: $2,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,400 · Education: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,400.19 |
| Education | $323.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $24,901.37 | 2019-2025 | Ninlaro, Alunbrig |
| Genentech USA, INC. | $19,527.85 | 2019-2025 | Venclexta, Tecentriq, Phesgo |
| Incyte Corporation | $5,241.18 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $4,444.10 | 2019-2024 | |
| Seagen INC. | $4,380.77 | 2019-2023 | Padcev, Tukysa, Adcetris |
| E.R. Squibb & Sons, L.L.C. | $2,260.37 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Astrazeneca Pharmaceuticals LP | $1,313.97 | 2019-2025 | Tagrisso, Lynparza, Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $1,050.47 | 2019-2025 | |
| Astellas Pharma US INC | $996.94 | 2019-2025 | Xtandi, Vyloy, Padcev |
| Janssen Biotech, INC. | $970.07 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Pfizer INC. | $939.14 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $858.66 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $643.23 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Amgen INC. | $609.73 | 2019-2023 | Lumakras |
| Abbvie INC. | $510.87 | 2019-2025 | Venclexta |
Show all 86 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvinder Bir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.